Table 1.
Demographic data of patients with schizophrenia (SZ) and healthy controls (HC)
| Schizophrenia patients (n = 25) | Healthy controls (n = 31) | p value | |
|---|---|---|---|
| Age (year) | 26.05 (4.9) | 25.73 (4.5) | 0.828 |
| SCIP | 68.74 (13.3) | 84.85 (6.2) | < 0.001 |
| CPZ (mg) | 476.63 (232.01) | ||
| Duration of illness (year) | 4.04 (4.9) | ||
| 3F PANSS+ | 12.92 (6.6) | ||
| 3F PANSS− | 14.23 (7.8) | ||
| 5F PANSS+ | 13.87 (5.6) | ||
| 5F PANSS− | 15.78 (7) | ||
| 5F PANSS disorganization | 15.3 (5.17) | ||
| 5F PANSS affect | 9.4 (2.95) | ||
| 5F PANSS resistance | 17.7 (2.7) |
Two participants from the SZ group did not complete the Positive and Negative Syndrome Scale (PANSS) assessment. 3F PANSS+ reflects the severity of positive symptoms, while 3F PANSS- that of negative symptoms — both according to the three factor structure. The following five scores were calculated according to the PANSS five factor structure: 5f PANSS+, 5F PANSS−, 5F PANSS Disorganization, 5F PANSS Affect, and 5F PANSS Resistance. Information on illness duration was only available for 24 patients, while only 23 completed the PANSS
SCIP Screen for Cognitive Impairment in Psychiatry (Purdon 2005), CPZ Chlorpromazine medication equivalent in mg